Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of *Pelargonium sidoides*, in animals models of cough, secretolytic activity and acute bronchitis

Yanyan Bao\textsuperscript{a}, Yingjie Gao\textsuperscript{a}, Egon Koch\textsuperscript{b}, Xin Pan\textsuperscript{a}, Yahong Jin\textsuperscript{a}, Xiaolan Cui\textsuperscript{a,}\textsuperscript{*}

\textsuperscript{a} Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China
\textsuperscript{b} Preclinical Research, Dr. Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany

\textbf{Article info}

Article history:
Received 27 February 2015
Accepted 6 March 2015

Keywords:
Antitussive
Secretolytic
Acute bronchitis
Airway infection
Herbal medicinal product
*Pelargonium sidoides*

\textbf{Abstract}

\textbf{Background:} EPs® 7630 is a proprietary aqueous-ethanolic extract from roots of *Pelargonium sidoides* DC and has been demonstrated to dispose among others of antibacterial, antiviral, immunomodulatory, antioxidant, and tissue-protective activity. It is an approved medicinal product in more than 50 countries for the treatment of airway infections such as acute bronchitis, common cold, and sinusitis.

\textbf{Purpose:} While the pharmacological effects of EPs® 7630 have extensively been evaluated in diverse \textit{in vitro} test systems, the number of publications reporting results from \textit{in vivo} models is limited.

\textbf{Study design:} In the present study antitussive, secretolytic, and anti-inflammatory effects of EPs® 7630 were assessed in animal experiments following oral administration at human equivalent doses.

\textbf{Methods:} Antitussive effects were evaluated using ammonia- and citric acid-induced models of cough in mice (20, 40, 120 mg/kg) and guinea pigs (10, 20, 45 mg/kg), respectively. For the determination of secretolytic activity tracheobronchial secretion of intraperitoneally injected phenol red was determined in mice, while antiinflammatory action was assessed in an acute bacterial bronchitis model in rats.

\textbf{Results:} A significant and dose-dependent reduction of cough frequency was observed in both cough models, which was accompanied by a prolongation of cough latency time. Similarly, the extract exerted a marked secretolytic activity in mice. Induction of acute bacterial bronchitis caused characteristic histopathological changes in lung tissue adjacent to trachea and bronchi. The degree of these lesions was significantly reduced in rats treated with EPs® 7630 at doses of 30 and 60 mg/kg. This protective effect at least partially seems to be mediated by an up-regulation of superoxide dismutase and a subsequent protective effect against oxidative stress as indicated by a reduced serum level of malondialdehyde.

\textbf{Conclusion:} The present data further support the therapeutic use of EPs® 7630 in respiratory tract infections and provide a basis for detailed studies on its bioactive constituents as well as their \textit{in vivo} mode of action.

\textcopyright{} 2015 Elsevier GmbH. All rights reserved.

\textbf{Introduction}

In southern Africa, different indigenous species of the plant genus *Pelargonium* are used in folk medicine for the treatment of various complaints, such as diarrhea, dysentery, liver disorders and dysmenorrhea. For more than a century, preparations from *P. reniforme* Curtis and/or *P. sidoides* DC. have also been used in European herbal medicine particularly for the therapy of tuberculosis and airway infections. A proprietary extract from the roots of *P. sidoides* (EPs® 7630) has been developed and registered with a full marketing authorization for the indication “acute bronchitis” by the German Federal Institute for Drugs and Medical Devices in 2005 (Brendler 2008). Therapeutic efficacy in this and related indications such as common cold, rhinosinusitis, tonsillitis, and chronic obstructive pulmonary disease has been evaluated in numerous randomized, double-blind and placebo-controlled trials as well as observational clinical study in patients from an age of one year upwards (Moyo and Van Staden 2014; Matthys et al. 2014). Safety and tolerability of EPs® 7630 has been demonstrated in 29 clinical trials and post-marketing surveillance studies involving more than 10,000 adults and children (Matthys et al. 2013).

EPs® 7630\textsuperscript{1} is a special aqueous ethanolic extract (11% m/m; drug extract ratio 1:8–10) characterized by a high content of

---

\textsuperscript{1} EPs® 7630 is the active ingredient of the product Umckaloabo® (ISO Arzneimittel, Ettlingen, Germany).
epigallo- and gallocatechin based polymeric polyphenols and a broad range of extensively oxygenated 1-benzopyran-2-one derivatives (Schötz et al. 2008). In vitro evaluation of pharmacological activities revealed among others mild to moderate direct antibacterial and antiviral properties, inhibition of bacterial adhesion on host cells as well as activation of the innate immune defense. This latter action is mediated by stimulation of release of tumor necrosis factor-alpha, nitric oxide, and interferon-beta, which are accompanied by an enhanced natural killer cell activity and an improved phagocytosis, oxidative burst and intracellular killing by human peripheral blood phagocytes. Besides, cytoprotective capabilities and an increase of ciliary beat frequency of nasal respiratory cells have been reported (Kolodziej 2011).

While the pharmacological effects of EPs® 7630 have extensively been investigated in diverse in vitro test systems, the number of publications reporting results from in vivo models is limited. In animal studies an inhibition of lipopolysaccharide-induced sickness behavior has been observed (Nöldner and Koch 2004; Nöldner and Schötz 2007), while no or only mild effects were seen on central nervous system activity in normal mice (Reynolds et al. 2004). In addition, antiviral action of EPs® 7630 has recently been confirmed in mice after inhalation of the extract (Theisen and Muller 2012). Thus, based on the main clinical indications for EPs® 7630 the present study concentrated on the evaluation of in vivo effects in an infective bronchitis model and two of the most common symptoms related to airway infections i.e. cough and disturbances in mucociliary clearance.

Materials and methods

Test substance

All investigations were performed with a single batch (No. 501790080/Ch.007) of the *Pelargonium sidoides* dry root extract EPs® 7630 kindly provided by the manufacturer Dr. Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany. In accordance with the EPs® 7630 standard dose of 60 mg/day for adolescents and adults (body weight 15–60 kg), equivalent doses on the basis of allometric means in mice, rats and guinea pigs would be about 15–36, 7–19 and 6–15 mg/kg/day, respectively. Based on this calculation, for the animal experiments doses which approximately correspond to once, twice or three times the average human equivalent dose for an adolescent person were chosen. Hence, the following doses were applied to mice (20, 40, 120 mg/kg/day); rats (15, 30, 60 mg/kg/day) and guinea pigs (10, 20, 45 mg/kg/day). All treatments were performed by gavage. EPs® 7630 was suspended in distilled water and applied in a volume of 0.2 ml/10 g in mice and 1 ml/100 g in rats and guinea pigs, respectively.

Reference drug

For reference purpose a radix glycyrrhizae oral solution (batch No. 130503) produced by DeRun Pharmaceutical Co., Ltd., Beijing, was employed. This product is approved in China as an expectorant for patients with respiratory infections i.e. cough and disturbances in mucociliary clearance. It was active in the experimental models used in the present study. In compliance with the dose in humans (30 ml/60 kg/day), equivalent oral doses on the basis of allometric means in mice (5 ml/kg/day), rats (2.75 ml/kg/day) and guinea pigs (2.15 ml/kg/day) were selected.

Experimental animals

Male and female ICR mice SPF-class; body weight of 20 ± 2 g) as well as male and female Wistar rats SPF-class, body weight 150 ± 10 g) were provided by Beijing Vital River Laboratory Animal Technology Co., Ltd. Guinea pigs (male and female, body weight 240 ± 20 g) were purchased from Beijing Jinmyuang Laboratory Animal Breeding Co., Ltd.

Animals were kept under standardized environmental conditions (12/12 h light-dark cycle, temperature 20–26 °C, 40–70% humidity) and had access to standard feed and tap water ad libitum. They were allowed at least 24 h for adaptation. At the end of the study the animals were euthanized by cervical dislocation. All animal experiments were approved by the Medical Ethics Committee, China Academy of Chinese Medical Sciences.

Bacteria

Streptococcus pneumoniae (31001) were acquired from Chinese Pharmaceutical and Biological Products and were stored at −80 °C until use.

Chemicals

The following chemicals were purchased from the suppliers given in brackets: citric acid (Beijing Chemical Reagent Company, batch No.: 060403), ammonia (Sinopharm Chemical Reagent Co., Ltd., batch No.: 20120918), phenol red (Solarbio Company, batch No.: 20114.12.07), nutrient broth (China Pharmaceutical and Biological Products), ether (Beijing Reagent Company, batch No.: 20090707), superoxide dismutase (SOD) ELISA kit (Nanjing Jiancheng Institute of Biotechnol- ogy, batch No.: 201209), malondialdehyde (MDA) ELISA kit (Nanjing Jiancheng Institute of Biotechnology, batch No.: 201209), and micro BCA protein assay kit (Kangwei Century Company, batch No.: 201209).

Evaluation of antitussive effects

Ammonia-induced coughing in mice

A total of 59 mice were randomly distributed according to their body weight to a control group, a radix glycyrrhizae group (5.5 ml/kg), and three EPs® 7630 groups with different doses (20, 40 and 120 mg/kg). Each treatment group consisted of 12 mice with an equal number of male and female animals. The drugs were applied once daily for three consecutive days by gavage at a volume of 0.2 ml/10 g. The control group was treated under the same conditions with 0.2 ml/10 g of distilled water. One hour after the last treatment mice were placed in a container with a volume of 1 l and exposed to a vapor from 1 ml of concentrated ammonia. After 20 s the animals were removed quickly and the latency to the first cough and the total number of coughs were registered over a period of 3 min. The relative cough latency time (in %) was calculated using the following formula:

\[
\frac{\text{cough latency time (sec) of test group}}{\text{cough latency time of control group}} \times 100\%
\]

Citric acid-induced coughing in guinea pigs

Suitable animals for the test were selected one day before the experiment. Guinea pigs which did not cough at all within 2 min after begin of exposure to a spray of citric acid solution or coughed less than 10 times during a 5 min observation period were discarded. According to the body weight a total of 50 selected guinea pigs were randomly distributed into a control group, a radix glycyrrhizae group (2.15 ml/kg), and three EPs® 7630 groups (10, 20, and 45 mg/kg). Each group consisted of 10 guinea pigs with an equal number of male and female animals. The drugs were administered intragastrically once a day at a volume of 1 ml/100 g for three consecutive days. The control group was treated under the same conditions with 1 ml/100 g of distilled water. One hour after the last dose, the guinea pigs were placed in a container with a volume of 7 l and exposed to a spray of 17.5% citric acid in water at a rate of 2 ml/min produced by a nebulizer at a constant pressure. One minute later, the latency time from begin of spraying to the first cough was registered. Thereafter,
the nebulization of citric acid solution was continued for a further 6 min and the number of coughs was subsequently registered for a period of 7 min. The relative cough latency time (%) was calculated as described above for ammonia-induced cough in mice.

**Bronchosecretolytic activity**

**Phenol red excretion in mice**

A total of 55 mice were randomly distributed to a control group, a radix Glycyrrhiza group (5.5 ml/kg), and three EPs® 7630 groups (20, 40, 120 mg/kg). Each group consisted of 11 mice with a similar proportion of male and female animals. The drugs were applied by gavage once a day at a volume of 0.2 ml/10 g for three consecutive days. Mice in the control group were treated under the same conditions with 0.2 ml/10 g of distilled water. Thirty minutes after the last dose, each mouse received an intraperitoneal injection of 0.5 ml of 2.5% phenol red solution. Half an hour later the animals were killed, the skin in the middle of the throat was cut, the tissue surrounding the trachea was removed, and a piece of trachea between the thyroid cartilage and the tracheal bifurcation was withdrawn. The trachea was rinsed five times with 2 ml 5% NaHCO₃ solution, and the lavage fluid was collected. The protein content of the bronchoalveolar lavage fluid was determined and a differential cell count was obtained. The lung was removed and subjected to histopathological examination. The following criteria were applied for grading the pathological changes:

“−”: Tracheal and bronchial epithelium shows no hyperplasia, no inflammation, lung tissue is normal

“+”: Tracheal and bronchial epithelium have mild segmental hyperplasia, inflammation is not obvious, no pulmonary interstitial inflammation, normal structure

“++”: Tracheal and bronchial epithelium has hyperplasia, surrounded by inflammation and vascular congestion

“+++”: Significant increase of lymphocytes in interstitial lung tissue. Tracheal and bronchial epithelium have significant hyperplasia, surrounded by diffuse inflammation and vascular congestion.

**Statistical analysis**

All data, except results of histopathological examination, are expressed as the mean ± standard deviation (SD). ANOVA was used for the determination of statistical significance (p < 0.05). For the pairwise comparison of groups the LSD test (homogeneity of variance) or the Dunnett T3 test (heterogeneity of variance) was applied. Statistical analyses were performed using SPSS software. Rank sum test was used for the statistical analysis of histopathological examination.

**Results**

**Antitussive effects of EPs® 7630 in an ammonia-induced cough model in mice**

Inhalation of ammonia vapor caused a first cough response in control animals within 25.2 ± 10.2 s and resulted in a total of 34.6 ± 19.9 coughs. Compared with the control group, cough frequency was significantly and dose-dependently reduced by up to 86% in animals receiving 20, 40, 120 mg/kg/day EPs® 7630. At the same time cough latency time was prolonged by the treatment between 182 and 367% (Table 1).

**Antitussive effects of EPs® 7630 in a citric acid-induced cough model in guinea pigs**

Antitussive effects of EPs® 7630 were confirmed in a widely used second pharmacological model employing citric acid-induced cough in guinea pigs. In comparison to the control group the number of coughs was reduced by 67, 63 and 73%, respectively, in animals treated with 10, 20, 45 mg/kg/day EPs® 7630. Although the mean cough latency time was markedly prolonged in EPs® 7630 treated guinea pigs this did not reach statistical significance due to a highly variable response of individual animals in the different groups (Table 2).

**Bronchosecretolytic effects of EPs® 7630 in mice**

Secretolytic activity was determined in mice by the secretion of intraperitoneally injected phenol red into the tracheobronchial tract over a period of 30 min. Elimination of the dye via the respiratory tract was dose-dependently increased after administration of EPs® 7630 for three consecutive days and this effect was statistically significant at doses of 40 and 120 mg/kg/day (Table 3).

### Table 1

| Group              | Dose   | Number of animals | Cough latency time (s) | Relative cough latency time (%) | Number of coughs |
|--------------------|--------|-------------------|------------------------|---------------------------------|------------------|
| Control            | –      | 11                | 25.2 ± 10.2            | –                               | 34.6 ± 19.9      |
| Radix glycyrrhize  | 5.5 ml/kg | 12              | 39.8 ± 19.8            | 159                             | 12.0 ± 8.3†      |
| EPs® 7630         | 20 mg/kg | 12               | 45.5 ± 24.5            | 182                             | 9.8 ± 7.3†       |
| EPs® 7630         | 40 mg/kg | 12               | 89.0 ± 53.4           | 356                             | 5.5 ± 5.7†       |
| EPs® 7630         | 120 mg/kg | 12             | 91.8 ± 49.2           | 367                             | 4.9 ± 4.1†       |

Values are mean ± SD.

† p < 0.05 compared to control.

‡‡ p < 0.01 compared to control.
Fig. 1. Effects of EPs<sup>®</sup> 7630 on acute bronchitis in rats. Compared with the normal control group the bronchitis model control group display substantial pathological changes. Treatment with EPs<sup>®</sup> 7630 at doses of 30 or 60 mg/kg significantly reduced the tracheal lesions (see Table 4).

### Table 2
Antitussive effects of EPs<sup>®</sup> 7630 in a citric acid-induced cough model in guinea pig.

| Group                | Dose     | Number of animals | Cough latency time (s) | Relative cough latency time (%) | Number of coughs |
|----------------------|----------|-------------------|------------------------|--------------------------------|-----------------|
| Control              | –        | 10                | 53.4 ± 20.6            | –                               | 20.0 ± 7.0      |
| Radix glycyrrhizae   | 2.15 ml/kg | 10                | 123.5 ± 65.0           | 231                             | 6.7 ± 6.5<sup>**</sup> |
| EPs<sup>®</sup> 7630 | 10 mg/kg  | 10                | 111.1 ± 114.0          | 208                             | 6.1 ± 5.4<sup>**</sup> |
| EPs<sup>®</sup> 7630 | 20 mg/kg  | 10                | 100.3 ± 116.9          | 188                             | 7.5 ± 7.0<sup>**</sup> |
| EPs<sup>®</sup> 7630 | 45 mg/kg  | 10                | 126.2 ± 162.2          | 236                             | 5.5 ± 4.3<sup>**</sup> |

Values are mean ± SD.  
<sup>**</sup><i>p</i> < 0.01 compared to control.

### Table 3
Bronchosecretolytic effects of EPs<sup>®</sup> 7630 in mice (phenol red secretion).

| Group                | Dose     | Number of animals | Concentration of phenol red (μg/ml) |
|----------------------|----------|-------------------|-----------------------------------|
| Control              | –        | 11                | 274.3 ± 89.1                     |
| Radix glycyrrhizae   | 5.5 ml/kg | 11                | 401.6 ± 104.4<sup>**</sup>       |
| EPs<sup>®</sup> 7630 | 20 mg/kg  | 11                | 349.1 ± 59.9                     |
| EPs<sup>®</sup> 7630 | 40 mg/kg  | 11                | 414.1 ± 113.1<sup>**</sup>       |
| EPs<sup>®</sup> 7630 | 120 mg/kg | 11               | 474.5 ± 116.7<sup>**</sup>       |

Values are mean ± SD.  
<sup>**</sup><i>p</i> < 0.01 compared to control.

### Table 4
Effects of EPs<sup>®</sup> 7630 on pathological changes in tracheae of rats with acute bacterial bronchitis.

| Group                | Dose     | Number of animals | Degree of tracheal lesions | p-value |
|----------------------|----------|-------------------|---------------------------|---------|
| Control              | –        | 12                | –                         | –       |
| Bronchitis control   | –        | 11                | –                         | –       |
| Radix glycyrrhizae   | 2.75 ml/kg | 11              | 2                         | 5 6     |
| EPs<sup>®</sup> 7630 | 15 mg/kg  | 12                | –                         | 6 4 2   |
| EPs<sup>®</sup> 7630 | 30 mg/kg  | 11                | –                         | 6 4 1   |
| EPs<sup>®</sup> 7630 | 60 mg/kg  | 12                | –                         | 6 6     |

### Table 5
Effects of EPs<sup>®</sup> 7630 on pathological changes in bronchi of rats with acute bacterial bronchitis.

| Group                | Dose     | Number of animals | Degree of bronchial lesions | p-value |
|----------------------|----------|-------------------|-----------------------------|---------|
| Control              | –        | 12                | –                           | –       |
| Bronchitis control   | –        | 11                | –                           | –       |
| Radix glycyrrhizae   | 2.75 ml/kg | 11              | –                           | 7 3 1   |
| EPs<sup>®</sup> 7630 | 15 mg/kg  | 12                | –                           | 9 2 1   |
| EPs<sup>®</sup> 7630 | 30 mg/kg  | 11                | –                           | 8 2 1   |
| EPs<sup>®</sup> 7630 | 60 mg/kg  | 12                | –                           | 9 2     |

### Discussion

Acute airway infections are among the most common reasons for consultation of a physician as well as absence from school or work due to illness. In the majority of cases respiratory infections are caused by viruses (e.g. adenoviruses, rhinoviruses, influenza and parainfluenza viruses, coronaviruses virus, respiratory syncytial virus, coxsackie viruses). They are usually self-limiting and in two thirds of cases will be cured within two weeks (Holzinger et al. 2014). Thus,
relief of symptoms and shortening of disease duration is the primary aim of medicinal treatment.

Viral infections of the respiratory tract ("common cold") are usually accompanied by an acute cough. Other symptoms include sore throat, runny nose, headache, growing pains, fatigue, and possibly fever. The transition from a common cold to an acute bronchitis is frequent. In the early stages of the inflammatory reaction patients are particularly afflicted by a dry cough. Following the release of inflammatory mediators or damage of the airway epithelium sensory nerves are activated which initiates the cough reflex. Although cough is normally a defensive reflex that keeps the respiratory tract free of obstructions and harmful substances, it is non-productive at this stage as mucus secretion is not yet increased. Due to its pure force coughing should not be combined with the application of protussive drugs due to the possibility that excessive respiratory secretion may accumulate in the airways. However, modern treatment concepts envisage a combination of antitussive and secretomucolytic activity since respiratory tract infections are rarely associated with a substantial mucus production and ongoing cough, particularly during the night, may be extremely debilitating for affected patients (Morice et al. 2002).

Although the beneficial therapeutic effects of EPs® 7630 in the treatment of respiratory tract infections has been demonstrated in a great number of randomized controlled clinical trials and are well supported by its until now described pharmacological profile, possible antitussive activity has not yet been investigated. In order to simulate the situation in the early stages of an acute bronchitis, a dry, non-productive cough was induced by chemical stimulation of sensory nerve receptors following inhalation of ammonia and citric acid in mice and guinea pigs, respectively. The results show that EPs® 7630 at pharmacologically relevant oral doses significantly cuts down cough frequency and also extends relative cough latency time in a dose-dependent manner in both species investigated.

Depending on their mode of action, medications used for the treatment of cough are usually classified as antitussive or protussive. Antitussive agents suppress the cough reflex by peripherally suppressing the stimulation of sensory neurons in the airways or centrally at the level of the cough center in the nucleus tractus solitarius and its integrating network (Reynolds et al. 2004). Protussive compounds improve the effectiveness of cough by improving the expectoration of airway secretion by increasing the volume of secretion (secretolytics), lowering the viscosity of mucus (mucolytics) or stimulation of mucociliary clearance by enhancing ciliary activity and mucin transport (secretomotorics).

With respect to citric acids-induced cough considerable similarity in conscious guinea pigs and men has been reported and a broad range of antitussive as well as protussive drugs have been observed to be active in this model, e.g. opioids, local anesthetics, histamine H1 receptor antagonists, 5-HT3 receptor agonists, ß-adrenergceptor agonists, antimuscarinics expectorants and mucolytics. Currently it is not known by which mechanism(s) EPs® 7630 exerts its cough inhibiting action. However, a central mode of action may not be excluded as EPs® 7630 previously has been demonstrated to suppress sickness behavior, a coordinated adaptation of behavior that develops during an infection in response to the central nervous action of inflammatory cytokines (Nöldner and Schötz 2007).

While cough in the early stages of an airway infection is considered as non-productive it is classified as productive with an ensuing increase of mucus production and expectoration. Stimulation of airway secretion is a first line-defense mechanism to clear the respiratory tract of foreign matter. Thus, it was considered worthwhile to evaluate if EPs® 7630 may also have an effect on tracheobronchial secretion. Measurement of secretolytic activity was evaluated by measuring the excretion of phenol red into respiratory tract (Coppi and Gatti 1989). Indeed, the extract was found to dose-dependently increase elimination of the dye via the respiratory tract with statistically significant effects at doses of 40 and 120 mg/kg. Thus, secretolytic activity could also contribute to the cough inhibiting action of EPs® 7630 by dilution and accelerated removal of the chemical stimuli whereby the later effect may be enhanced by the previously reported increase of ciliary beat frequency in the presence of the extract (Neugebauer et al. 2005).

Previously, concern has been expressed that antitussive therapy should not be combined with the application of protussive drugs due to the possibility that excessive respiratory secretion may accumulate in the airways. However, modern treatment concepts envisage a combination of antitussive and secretomucolytic activity since respiratory tract infections are rarely associated with a substantial mucus production and ongoing cough, particularly during the night, may be extremely debilitating for affected patients (Morice et al. 2002).

Besides its beneficial effects in acute bronchitis (Matthys and Kamin 2011), EPs® 7630 has previously been shown to prolong time to exacerbation of chronic bronchitis and quality of life in patients with chronic obstructive pulmonary disease (Matthys et al. 2010). Thus, the present preclinical study on in vivo activity of EPs® 7630 after oral application was supplemented by examining its effect in a bacterial bronchitis in rat as well. Although daily inhalation of unburned smoke over a period of 21 days in combination with weekly intranasal applications of Streptococcus pneumoniae had no effect on the number of leucocytes and the protein content in the bronchoalveolar lavage, histopathological examination clearly demonstrated an ongoing inflammatory reaction. These pathological changes were dose-dependently reduced around the tracheae of treated animals when compared with the model control group while a significant effect on bronchial histopathology was only seen at a dose of 30 mg/kg. This protective effect at least partially seems to be mediated by an up regulation of SOD and a subsequent protective effect against oxidative stress as indicated by a reduced serum level of MDA.

A wide selection of compounds has been isolated and identified in EPs® 7630 (Schötz and Nöldner 2007). Characteristic constituents of the extract are highly oxygenated coumarins, simple phenols (e.g., catechin, gallocatechin) and high molecular weight proanthocyanidins. In general, the coumarins and polymeric polyphenols are described as the main pharmacologically active agents in EPs® 7630.

Table 6

| Group                  | Dose   | Number of animals | SOD (U/ml) | MDA (nmol/ml) |
|------------------------|--------|-------------------|------------|---------------|
| Normal control         | –      | 12                | 99.5 ± 62.1| 4.66 ± 1.47   |
| Bronchitis control     | –      | 11                | 188.2 ± 82.1| 4.49 ± 1.09   |
| Radix glycyrrhiza      | 2.75 ml/kg | 11          | 128.8 ± 110.9| 4.44 ± 0.96   |
| EPs® 7630              | 15 mg/kg | 12          | 242.3 ± 40.1 | 4.36 ± 1.16   |
| EPs® 7630              | 30 mg/kg | 11          | 263.1 ± 62.1*| 4.49 ± 1.03   |
| EPs® 7630              | 60 mg/kg | 12          | 213.0 ± 79.2 | 3.53 ± 0.83*  |

Values are mean ± SD.

* p < 0.05 compared to bronchitis control.
** p < 0.01 compared to normal control.
Kolodziej, 2007, 2011). However, due to their high degree of polymerization it has been questioned if the proanthocyanidins may at all contribute to the pharmacological action of EPs® 7630 after oral administration (Kolodziej 2007). Thus, the present experiments were designed to investigate antitussive, secretolytic and anti-inflammatory effects of EPs® 7630 in animal experiments following oral administration of human equivalent doses. The now generated data definitely support the oral therapeutic use of EPs® 7630 in respiratory tract infections and provide a basis for further studies on its bioactive constituents as well as their in vivo mode of action.

Conflict of interest

Yanyan Bao, Yingjie Gao, Xin Pan, Yahong Jin and Xiaolan Cui are employees of Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China, and do not have any conflict of interest. Egon Koch is employee of Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe (Germany).

Acknowledgment

This study was supported by Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe (Germany).

References

Brendler, T., Van Wyk, B.E., 2008. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). J. Ethnopharmacol. 119, 420–433.

Copp, G., Catti, M.T., 1989. A method for studying expectorant action in the mouse by measurement of tracheobronchial phenol red secretion. Farmaco 44, 541–545.

Holzinger, F., Beck, S., Dini, L., Stoeter, Ch., Heintze, Ch., 2014. Diagnose und Therapie des akuten Hustens bei Erwachsenen (Klinische Leitlinie). Dtsch. Aerztekbl. Int. 111, 356–363.

Kolodziej, H., 2007. Fascinating metabolic pools of Pelargonium sidoides and Pelargonium reniforme, traditional and phytomedicinal sources of the herbal medicine Umckaloabo®. Phytomedicine 14 (Suppl. 6), 9–17.

Kolodziej, H., 2011. Antimicrobial, antiviral and immunomodulatory activity studies of Pelargonium sidoides (EPs® 7630) in the context of health promotion. Pharmaceuticals 4, 1295–1314.

Matthys, H., Lizogub, V.G., Malek, F.A., Kieser, M., 2010. Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides. Curr. Med. Res. Opin. 26, 1413–1422.

Matthys, H., Kamin, W., 2011. EPs 7630, a herbal drug preparation for treating acute bronchitis in children and adults. Approaches to Bronchitis, Chapter 6, pp. 53–70.

Matthys, H., Pliskevich, D.A., Bondarchuk, O.M., Malek, F.A., Tribanek, M., Kieser, M., 2013. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD. Respir. Med. 107, 691–701.

Matthys, H., Malek, F.A., Kamin, W., 2014. EPs® 7630 in acute respiratory tract infections – a systematic review and meta-analysis of randomised clinical research. Forsch. Komplementarmed. 21 (Suppl. 1), 57–58.

Morice, A.H., Widdicombe, J., Dickinngatis, P., Groenke, L., 2002. Understanding cough. Eur. Respir. J. 19, 6–7.

Moyo, M., Van Staden, J., 2014. Medicinal properties and conservation of Pelargonium sidoides DC. J. Ethnopharmacol. 152, 243–255.

Neugebauer, P., Mickenhagen, A., Sieler, D., Walger, M., 2005. A new approach to pharmacological effects on ciliary beat frequency in cell cultures – exemplary measurements under Pelargonium sidoides extract (EPs 7630). Phytomedicine 12, 46–51.

Nöldner, M., Koch, E., 2004. Inhibition of endotoxin-induced sickness behaviour in mice by an extract from roots of Pelargonium sidoides (Umckaloabo). Focus on alternative and complementary therapies. In: Abstracts of the 11th Annual Symposium on Complementary Health Care. 17th–19th November 2004, Exeter, UK, pp. 9–20.

Nöldner, M., Schötz, K., 2007. Inhibition of lipopolysaccharide-induced sickness behavior by a dry extract from the roots of Pelargonium sidoides (EPs® 7630) in mice. Phytomedicine 14 (Suppl. 6), 27–31.

Reynolds, S.M., Mackenzie, A.J., Spina, D., Page, C.P., 2004. The pharmacology of cough. Trends Pharmacol. Sci. 25, 569–576.

Schötz, K., Nöldner, M., 2007. Mass spectroscopic characterisation of oligomeric proanthocyanidins derived from an extract of Pelargonium sidoides roots (EPs® 7630) and pharmacological screening in CNS models. Phytomedicine 14 (Suppl. 6), 32–39.

Schötz, K., Erdelmeier, C., Germer, S., Hauer, H., 2008. A detailed view on the constituents of EPs® 7630. Planta Med. 74, 667–674.

Theisen, L.L., Muller, C.P., 2012. EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. Antivir. Res. 94, 147–156.